Information  X 
Enter a valid email address

SYNCONA (SYNC)

Related News

10-Aug-2020 07:06 AM

Syncona posts quarterly return of 13.5%

Life sciences company investor Syncona said it posted a positive return in the June quarter amid an increase in the value of its portfolio companies. The company's net asset value return for the three months through June was 13.5%, with net assets o
11-Jun-2020 08:45 AM

Syncona reports fall in net assets as performance hit by 81% Autolus share price fall

Healthcare investor Syncona has reported a 13.3% decline in NAV total return in its final results, with net assets down to £1,246.5m at year end, as performance was impacted by a drop in Autolus' share price. For the year ended 31 March 2020,
23-Mar-2020 08:00 AM

Syncona expects portfolio companies to delay clinical trials due to Covid-19

Healthcare company investor Syncona said it expected its portfolio companies' clinical trials to be delayed due to the coronavirus outbreak. 'While it is hard to forecast the precise impact, we would anticipate delays to a number of our clinica
24-Feb-2020 08:10 AM

Broker Forecast - Peel Hunt issues a broker note on Syncona Ltd

Peel Hunt today initiates coverage of Syncona Ltd (LON:SYNC) with a add investment rating and price target of 286p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
04-Feb-2020 08:17 AM

Syncona net asset value edges up in third quarter

Life sciences company investor Syncona said its net asset value total return had crept up 0.2% in its fiscal third quarter. The rise had slightly reduced to 7.0% the fall in the company's net asset value total return for the nine months through Dece
21-Nov-2019 08:13 AM

Syncona posts 7.2% NAV loss despite strong sales

Healthcare investment company Syncona reported a 7.2% loss for the six months to the end of September as its portfolio was weighted down by a fall in the share price of one of its holdings. Autolus, a NASDAQ-listed therapeutics company, declined by 61% d
12-Aug-2019 07:11 AM

Syncona valuation falls in June quarter despite asset sales

Healthcare company investor Syncona said its net asset value fell by 7% in the June quarter after it sold investments Blue Earth Diagnostics and Nightstar. The company sold Nightstar to Biogen, with £255.8m of proceeds received in the period, repre
01-Aug-2019 09:38 AM

Syncona completes sale of Blue Earth Diagnostics for $476.3m

Life science investment trust Syncona said it had completed the sale of its portfolio company Blue Earth Diagnostics to Bracco Imaging for $476.3m (£390.2m). The sale of Blue Earth would generate £336.9m of net proceeds for Syncona for its 89
27-Jun-2019 08:51 AM

Syncona sells Blue Earth Diagnostics for $450m

Syncona said it had agreed to sell its portfolio company Blue Earth Diagnostics to global diagnostic imaging leader Bracco Imaging for $450m, plus a closing adjustment of around $25m. The sale was expected to close in the third quarter of 2019. Syncona
11-Apr-2019 08:21 AM

Syncona merges ophthalmology firms to create leading retinal gene therapy platform

Healthcare company Syncona announced that its companies, Gyroscope Therapeutics and Orbit Biomedical, would merge to create the first fully integrated retinal gene therapy platform with clinical, delivery and manufacturing capabilities. The merger would
13-Feb-2019 07:21 AM

Syncona performance slips in December quarter as Nightstar shares fall

Healthcare company investor Syncona said its performance slipped over the December quarter due to a fall in the share price of portfolio company Nightstar. For the three months through December, Syncona posted a total return of negative 6.6%. However, o
21-Nov-2018 07:39 AM

Syncona posts 33% jump in performance; to invest at top of guidance range

Life sciences investor Syncona said it had boosted its first-half net asset value per share by 33%, as its portfolio of companies generated higher returns. Net assets at 30 September were worth £1.39bn, or 208.1p per share. The company said it had
13-Nov-2018 07:41 AM

Syncona portfolio company Nighstar books loss; starts new clinical trial

Life sciences company investor Syncona noted that portfolio company Nightstar Therapeutics had booked a third-quarter net loss owing to increased R&D spending. Nightstar, which develops treatments for rare inherited retinal diseases, also said it had kic
14-Jun-2018 08:13 AM

Syncona delivers strong returns and an increase in NAV

Syncona revealed strong returns and an increase in net asset value (NAV) with a positive performance across the company in the year to 31 March. Net assets were £1,055.8m, 158.9p per share, representing a total return of 18.7%. OPERATIONAL HIGHLIG
22-Nov-2017 07:49 AM

Syncona NAV rises 16.7% in first half

Syncona said its net asset value per share increased by 16.7% in the first half, as it boosted returns in its life sciences portfolio. The company said it now has assets of £1.03b, up from £895.2m in the previous correspond period. "Wi
16-Apr-2012 07:44 AM

Major board changes at Synchronica

Synchronica has announced several changes to the Board of Directors following the offer for Synchronica by Myriad Group AG being declared unconditional in all respects. Simon Wilkinson has been appointed Executive Chairman and James Bodha has been appoin
04-Apr-2012 09:23 AM

Myriad board urges Synchronica to accept offer

On 7 March 2012, the Board of Myriad announced the terms of its recommended increased share offer for the entire issued and to be issued share capital of Synchronica. Under the terms of the Offer, Synchronica Shareholders will receive 4.83 New Myriad Sh
20-Feb-2012 08:42 AM

Synchronica signs partnership deal with NewPace

Synchronica has signed a letter of intent with Canada's NewPace Technology Development to cooperate in the development, sales and marketing of a Rich Communication Suite (RCS) product. Rich Communication Suite (RCS) is a mobile industry standards e
14-Feb-2012 01:26 PM

Synchronica clinches deal for entry-level Smartphones

Next-generation mobile messaging services provider Synchronica has won a contract with a device manufacturer targeting the Americas. Synchronica's white-labelled Mobile Gateway will be bundled on to the manufacturer's entry-level Smartphone d
08-Feb-2012 09:47 AM

Synchronica signs Letter of Intent with Intertainment Media.

Synchronica has signed a Letter of Intent with Intertainment Media. Synchronica, a provider of next-generation mobile messaging services and Intertainment Media intend to integrate Synchronica's flagship messaging platform, Mobile Gateway, with In
16-Jan-2012 12:59 PM

Cost cutting boosts Synchronica

Synchronica announced last that it expects to report full year revenues of approximately $23m for the year ended 31 December 2011. It has now revealed that, according to unaudited data from its internal management reports, the company was profitable at
13-Jan-2012 10:33 AM

Synchronica doubles its revenues last year

Synchronica, the international provider of next-generation mobile messaging services, believes it will produce results for 2011 marginally ahead of market expectations. In a trading update Synchronica says it expects to report full year 2011 revenues of
05-Jan-2012 02:29 PM

Myriad confirms talks over Synchronica

Myriad has confirmed it is holding preliminary talks about a possible offer for with Synchronica. Myriad said the potential acquisition would enhance its position as a global leader in mobile messaging software, serving (on a combined basis) more than 10
09-Dec-2011 07:31 AM

Synchronica wins order with mobile manufacturer

Synchronica(LON:SYNC), provider of next-generation mobile messaging services, has announced an expansion order for professional services from an existing Tier-1 mobile device manufacturer customer. The order, which is valued at $580,000, enables Synchron
24-Nov-2011 09:04 AM

Massive recurring revenue boost for Synchronica

Synchronica, the next-generation mobile messaging services, has announced US$7.0 million revenue for the third quarter, a 900% improvement from the same period 2010 (Q3'10: US$0.7 million). The company also reported a 1098% growth in recurring rev
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t